Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

REGN has been the topic of a number of other research reports. Canaccord Genuity Group increased their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Wells Fargo & Company raised their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Finally, JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $803.17 on Monday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $762.17 and a 200-day simple moving average of $666.58. The stock has a market cap of $84.91 billion, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $12.07 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,636 shares of company stock worth $2,862,920 in the last 90 days. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of REGN. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $226,000. MGO One Seven LLC lifted its stake in shares of Regeneron Pharmaceuticals by 28.1% in the 2nd quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 106 shares during the period. Mutual Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.0% in the 2nd quarter. Mutual Advisors LLC now owns 888 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 50 shares during the period. Finally, Private Trust Co. NA boosted its holdings in shares of Regeneron Pharmaceuticals by 16.5% in the second quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 27 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.